Effects of combining taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 923-928

  Li, Wei ^a   Tang, Yun Xian ^a   Wan, Liang ^a   Cai, Jia Hui ^a   Zhang, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; Cell apoptosis; Microvessel density; Ovarian cancer; SC 560; Taxol; Vascular endothelial growth factor

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; MESSENGER RNA; PACLITAXEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

EID: 84872729700     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1086     Document Type: Article

References (42)

1. Ozols RF: Future directions in the treatment of ovarian cancer. Semin Oncol 29: 32-42, 2002.
2. Yokoyama Y, Sakamoto T, Sato S and Saito Y: Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol 20: 361-366, 1999.
3. Ozols RF: Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20: 1161-1163, 2002.
4. Kohler DR and Goldspiel BR: Evaluation of new drugs: Paclitaxel (taxol). Pharmacotherapy 14: 3-34, 1994.
5. Pignata S, Scambia G, Ferrandina G, et al: Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29: 3628-3635, 2011.
6. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL and Li LZ: Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56: 365-375, 2011.
7. Subbaramaiah K, Hart JC, Norton L and Dannenberg AJ: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275: 14838-14845, 2000.
8. Sorokin A: Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10: 647-657, 2004.
9. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS and Munkarah A: Cyclooxygenase-2 inhibitior inhibits PI3-K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126: 382-394, 2010.
10. Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J, Gong H and Cai Y: Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest 26: 822-829, 2008.
11. Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A and Patsouris E: The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 204: 241-249, 2008.
12. Ferrandina G, Ranelletti FO, Martinelli E, Paglia A, ZannoniGF and Scambia G: Cyclooxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 6: 182, 2006.
13. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
14. Olsen SR: Taxanes and COX-2 inhibitors from molecular pathways to clinical practice. Biomed Pharmacother 59 (Suppl2): S306-S310, 2005.
15. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ and Sukhatme VP: Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by COX-2 inhibition. Int J Cancer 113: 490-498, 2005.
16. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and Dubois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906-911, 2003.
17. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBoisRN and Dey SK: Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 65: 3735-3744, 2005.
18. Daikoku T, Tranquch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC and Dey SK: Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66: 2527-2531, 2006.
19. Li W, Wang J, Jiang HR, Xu XL, Zhang J, Liu ML and Zhai LY: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci 12: 668-681, 2011.
20. Williams CS, Watson AJ, Sheng H, Helou R, Shao J and DuBoisRN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045-6051, 2000.
21. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
22. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
23. del Vecchio MT, Leoncini L, Buerki K, Kraft R, Megha T, Barbini P, Tosi P and Cottier H: Diffuse controcytic and/or centroblastic malignant non-Hodgkins lymphomas: comparison of mitotic and pyknotic (apoptotic) indices. Int J Cancer 47: 38-43, 1991.
24. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC and Tangrea JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
25. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, FliederDB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ: Celecoxib, a selective cyclo-Oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21(14): 2645-2650, 2003.
26. Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, LoVullo S, Mansueto G, Bonginelli P, Gattuso D and Gion M: The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer a phase II study with biological correlates. Cancer J 11: 209-216, 2005.
27. Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes RS, Beneck D, Paul S, Stiles BM, Zhang Y and Schrump DS: Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol 6: 1121-1127, 2011.
28. Bhatt RS, Merchan J, Parker R Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D and Sukhatme VP: A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116: 1751-1756, 2010.
29. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F and Choy H: A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 15: 2158-2165, 2009.
30. Kitamura T, Itoh M, Noda T, Matsuura M and Wakabayashi K: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 109: 576-580, 2004.
31. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular endothelial growth factor (VEGF) in epithelia ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227, 1997.
32. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
33. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
34. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
35. Li W, Xu RJ, Lin ZY, Zhuo GC and Zhang HH: Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor. Med Oncol 26: 170-177, 2009.
36. Dore M, Cote LC, Mitchell A and Sirois J: Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 46: 77-84, 1998.
37. Gastman BR: Apoptosis and its clinical impact. Head Neck 23: 409-425, 2001.
38. Foa R, Norton L and Seidman AD: Taxol (paclitaxel): A novel antimicrotubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 24: 6-14, 1994.
39. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002.
40. Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN and Dey SK: Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res 67: 5285-5292, 2007.
41. Bottone FG Jr, Martinez JM, Alston-Mills B and Eling TE: Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 25: 349-357, 2004.
42. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE and ChenCS: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94: 1745-1757, 2002.